Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara H McGovern

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Infectious Diseases and Therapy|June 28, 2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Infectious Diseases and Therapy|June 28, 2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 4